HuGE Literature Finder
Records
1
-
4
Pharmacogenetic landscape of Metabolic Syndrome components drug response in Tunisia and comparison with worldwide populations. PloS one 2018 13 (4): e0194842. Jmel Haifa, Romdhane Lilia, Ben Halima Yosra, Hechmi Meriem, Naouali Chokri, Dallali Hamza, Hamdi Yosr, Shan Jingxuan, Abid Abdelmajid, Jamoussi Henda, Trabelsi Sameh, Chouchane Lotfi, Luiselli Donata, Abdelhak Sonia, Kefi R |
Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2015 Jul 26 (5): 499-504. Ghozlan Manal F, Foad Dina A, Darwish Yasser W, Saad Abeer |
Genetic and clinical determinants influencing warfarin dosing in children with heart disease. Pediatric cardiology 2012 Nov . Nguyen N, Anley P, Yu MY, Zhang G, Thompson AA, Jennings LJ |
Increased warfarin consumption and residual fibrin turnover in thrombotic patients with primary antiphospholipid syndrome. Thrombosis research 2011 Jun 127 (6): 595-9. Ames Paul R J, Margaglione Maurizio, Ciampa Antonio, Colaizzo Donatella, Ferrara Felicetto, Iannaccone Luigi, Vincenzobrancacci |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jul 06, 2022
- Content source: